By Fineline Cube Johnson & Johnson (J&J, NYSE: JNJ) announced on June 26, 2026, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of an indication extension for TECVAYLI (teclistamab) in combination with daratumumab for treating adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy.
Regulatory Milestone Timeline
| Date | Regulatory Action | Indication |
|---|---|---|
| Aug 2022 | EC Approval | RRMM patients with ≥3 prior therapies (IMiD, PI, anti-CD38) |
| Aug 2023 | EC Type II Variation | Reduced dosing frequency (1.5mg/kg every 2 weeks) for CR+ patients ≥6 months |
| Jun 2026 | CHMP Positive Opinion | Combination with daratumumab for ≥1 prior therapy patients |
Drug Profile & Mechanism
- Teclistamab: Bispecific antibody targeting BCMA (B-cell maturation antigen) and CD3 (T-cell receptor)
- Daratumumab: CD38-directed monoclonal antibody with complementary mechanism of action
- Combination Rationale: Dual targeting enhances anti-myeloma activity through synergistic immune activation
- Current Status: Already approved in EU for heavily pretreated RRMM patients
Clinical Evidence – MajesTEC-3 Phase 3 Study (NCT05083169)
| Endpoint | Teclistamab + Daratumumab | Standard of Care | Result |
|---|---|---|---|
| Progression-Free Survival | Not reached | 7.2 months | Statistically significant improvement |
| Overall Survival | Ongoing analysis | Reference arm | Statistically significant improvement |
| Patient Population | ≥1 prior therapy | Same criteria | Earlier treatment line |
The MajesTEC-3 study demonstrated that the combination achieved statistically significant improvements in both progression-free survival (PFS) and overall survival (OS) compared to standard of care in patients with fewer prior treatment lines than previously approved.
Market Impact & Strategic Significance
- Expanded Patient Population: Moves treatment into earlier disease setting (≥1 prior therapy vs. ≥3 prior therapies)
- Competitive Positioning: Strengthens J&J’s position in the growing BCMA-targeted multiple myeloma market
- Revenue Potential: Earlier-line treatment typically captures larger patient populations and longer treatment durations
- Next Steps: European Commission decision expected within 67 days of CHMP recommendation
- Global Strategy: Supports broader development program for teclistamab combinations across treatment lines
This indication extension represents a significant advancement in making this innovative bispecific therapy available to patients earlier in their treatment journey, potentially improving long-term outcomes in multiple myeloma.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical trial results, and commercial expectations. Actual results may differ due to regulatory decisions, competitive developments, and market dynamics.-Fineline Info & Tech